STOCK TITAN

Milestone Pharmaceuticals (NASDAQ: MIST) director receives 77,000 stock options grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Milestone Pharmaceuticals Inc. director Andrew Saik received a grant of stock options as part of his compensation. The award covers 77,000 options to buy common stock at an exercise price of $1.22 per share.

The options vest in twelve equal monthly installments starting on July 10, 2026, and will in any case be fully vested by the date of the company’s next annual stockholder meeting, as long as Saik continues to provide service through each vesting date. Following this grant, he holds 77,000 options directly.

Positive

  • None.

Negative

  • None.
Insider Saik Andrew
Role null
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 77,000 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 77,000 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Options granted 77,000 options Grant to director Andrew Saik
Exercise price $1.22 per share Stock option strike price
Expiration date June 10, 2036 Option term end
Underlying shares 77,000 shares Common stock underlying options
Post-grant option holdings 77,000 options Total options held directly after grant
Vesting schedule 12 equal monthly installments Beginning July 10, 2026
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
derivative security financial
"transaction_type: derivative"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
exercise price financial
"conversion_or_exercise_price: 1.2200"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"This option will vest in twelve (12) equal monthly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"expiration_date: 2036-06-10T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Saik Andrew

(Last)(First)(Middle)
C/O MILESTONE PHARMACEUTICALS INC.
1111 DR. FREDERIK-PHILIPS BLVD, STE 420

(Street)
MONTREALH4M 2X6

(City)(State)(Zip)

QUEBEC, CANADA

(Country)
2. Issuer Name and Ticker or Trading Symbol
Milestone Pharmaceuticals Inc. [ MIST ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$1.2206/10/2026A77,000 (1)06/10/2036Common Stock77,000$077,000D
Explanation of Responses:
1. This option will vest in twelve (12) equal monthly installments, beginning on July 10, 2026, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date.
/s/ Joseph Oliveto, Attorney-in-Fact06/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Milestone Pharmaceuticals (MIST) director Andrew Saik report in this Form 4?

Andrew Saik reported receiving a grant of stock options for 77,000 shares of Milestone Pharmaceuticals common stock. These options are compensation, not open-market purchases, and give him the right to buy shares at a fixed exercise price of $1.22 per share.

How many stock options did Andrew Saik receive from Milestone Pharmaceuticals (MIST)?

Andrew Saik received stock options for 77,000 shares of Milestone Pharmaceuticals common stock. The options are a derivative security, meaning they represent the right to purchase shares in the future under specified terms rather than current share ownership.

What is the exercise price and term of Andrew Saik’s Milestone (MIST) stock options?

The options have an exercise price of $1.22 per share and expire on June 10, 2036. This gives Saik a long-dated right to buy Milestone common stock at that price if the options vest and he chooses to exercise them.

How do the Milestone Pharmaceuticals (MIST) options granted to Andrew Saik vest?

The options vest in twelve equal monthly installments beginning July 10, 2026. They will be fully vested by the date of Milestone Pharmaceuticals’ next annual stockholder meeting, assuming Saik continues to provide service through each vesting date.

Is Andrew Saik’s Form 4 transaction for Milestone (MIST) a stock sale or purchase?

The Form 4 shows an acquisition of derivative securities as a grant or award, not an open-market stock sale or purchase. Saik received 77,000 stock options as compensation, classified as an “A” code transaction for a grant or award acquisition.